前收市價 | 0.1300 |
開市 | 0.1300 |
買盤 | 0.0000 |
賣出價 | 0.0000 |
拍板 | 15.00 |
到期日 | 2024-06-21 |
今日波幅 | 0.1300 - 0.1300 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 無 |
The average of price targets set by Wall Street analysts indicates a potential upside of 99.9% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.